Suntory Pharmaceutical   Report issue

For profit Phase 2 Phase 3
Founded: Osaka Japan (1899)
Status: Left NME R&D (2011)

Organization Overview

First Clinical Trial
1999
NCT00030121
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Brand's Suntory Asia | Lucozade Ribena Suntory

Active Ingredients

Drugs in Phase 3 Trials (2)

chicken extract (1 trial)

rpaf-ah (1 trial)

Drugs in Phase 2 Trials (1)

atrial natriuretic peptide (1 trial)

Drugs in Other Trials (7)

blackcurrant extract (1 trial)

citrus extract (1 trial)

fiber (1 trial)

l-epigallocatechin (2 trials)

polyphenols (1 trial)

tea (1 trial)

tea extracts (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Sepsis (Phase 3)

Syndrome (Phase 2)

Toxemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 10